93 related articles for article (PubMed ID: 9025746)
1. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi.
Kapucu LO; Akyüz C; Vural G; Oguz A; Atasever T; Büyükpamukçu M; Unlü M
J Nucl Med; 1997 Feb; 38(2):243-7. PubMed ID: 9025746
[TBL] [Abstract][Full Text] [Related]
2. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: Comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response.
Ilhan IE; Vural G; Berberoglu S; Kapucuoglu N; Cila A; Eke S
Pediatr Hematol Oncol; 2005 Mar; 22(2):153-62. PubMed ID: 15805001
[TBL] [Abstract][Full Text] [Related]
3. Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin's lymphoma.
Song HC; Lee JJ; Bom HS; Chung IJ; Kim HJ; Park YK; Kim EE
Clin Nucl Med; 2003 Jun; 28(6):457-62. PubMed ID: 12911092
[TBL] [Abstract][Full Text] [Related]
4. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Tsuchiya H; Tomita K; Nonomura A; Tonami N
J Nucl Med; 1997 Apr; 38(4):501-6. PubMed ID: 9098190
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report.
Kao CH; Tsai SC; Wang JJ; Ho YJ; Ho ST; Changlai SP
Int J Cancer; 2001 Jul; 95(4):228-31. PubMed ID: 11400115
[TBL] [Abstract][Full Text] [Related]
6. Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma.
Koutsikos J; Athanasoulis T; Anagnostopoulos A; Velidaki A; Passadi M; Dimopoulos MA; Zerva C
J Nucl Med; 2005 Jun; 46(6):978-82. PubMed ID: 15937309
[TBL] [Abstract][Full Text] [Related]
7. Comparative feasibility of separate or simultaneous rest thallium-201/stress technetium-99m-sestamibi dual-isotope myocardial perfusion SPECT.
Kiat H; Germano G; Friedman J; Van Train K; Silagan G; Wang FP; Maddahi J; Berman D
J Nucl Med; 1994 Apr; 35(4):542-8. PubMed ID: 8151372
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer.
Yamamoto Y; Nishiyama Y; Satoh K; Takashima H; Ohkawa M; Fujita J; Kishi T; Matsuno S; Tanabe M
J Nucl Med; 1998 Sep; 39(9):1626-9. PubMed ID: 9744357
[TBL] [Abstract][Full Text] [Related]
9. Scintigraphic evaluation of pancreatic transplants using technetium-99m-sestamibi.
Elgazzar AH; Munda R; Fernandez-Ulloa M; Clark J; Ryan JR; Hughes JA
J Nucl Med; 1995 May; 36(5):771-7. PubMed ID: 7738646
[TBL] [Abstract][Full Text] [Related]
10. Monitoring response to therapy with thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma.
Kostakoglu L; Uysal U; Ozyar E; Hayran M; Uzal D; Demirkazïk FB; Kars A; Atahan L; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1009-14. PubMed ID: 9225780
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc sestamibi as a prognostic factor of response to first-line therapy and outcome in patients with malignant lymphoma.
Spyridonidis TJ; Matsouka P; Symeonidis A; Savvopoulos C; Vassilakos PJ; Apostolopoulos DJ
Clin Nucl Med; 2013 Nov; 38(11):847-54. PubMed ID: 24089060
[TBL] [Abstract][Full Text] [Related]
12. Limitations of craniocaudal thallium-201 and technetium-99m-sestamibi mammoscintigraphy.
Maurer AH; Caroline DF; Jadali FJ; Manzone TA; Maier WP; Au FC; Schnall SF
J Nucl Med; 1995 Sep; 36(9):1696-700. PubMed ID: 7658233
[TBL] [Abstract][Full Text] [Related]
13. 99mTechnetium-SESTAMIBI uptake in malignant lymphomas. Correlation with chemotherapy response.
Lazarowski A; Dupont J; Fernández J; Garay G; Florín A; Solimano J; Riveros D; Cacchione R
Lymphat Res Biol; 2006; 4(1):23-8. PubMed ID: 16569203
[TBL] [Abstract][Full Text] [Related]
14. [Value of scintigraphy with 99mTc-MIBI in the diagnosis and follow-up of Hodgkin's and non-Hodgkin's lymphomas].
Solano Bravo ME; Perera Pintado A; Gómez Pérez JR; Rodríguez Pérez JL; Sánchez Mendoza EL; Pérez Valdés M; Sánchez Del Campo Romero M
Rev Esp Med Nucl; 2000 Apr; 19(2):85-91. PubMed ID: 10799923
[TBL] [Abstract][Full Text] [Related]
15. [Myocardial perfusion scintigraphy with 99mTC-sestamibi and gated SPECT and myocardial perfusion scintigraphy with reinjection of 201Tl at 24 hours. Are the techniques comparable?].
Fuster D; Solà M; Magriñá J; García A; Pavía J; Vidal-Sicart S; Huguet M; Muxí A
Rev Esp Med Nucl; 1999 Jun; 18(3):169-75. PubMed ID: 10431064
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of planar technetium-99m-sestamibi myocardial perfusion images using modified background subtraction.
Koster K; Wackers FJ; Mattera JA; Fetterman RC
J Nucl Med; 1990 Aug; 31(8):1400-8. PubMed ID: 2143529
[TBL] [Abstract][Full Text] [Related]
17. Thallium-201 scintigraphy in pediatric soft-tissue tumors.
Howman-Giles R; Uren RF; Shaw PJ
J Nucl Med; 1995 Aug; 36(8):1372-6. PubMed ID: 7629580
[TBL] [Abstract][Full Text] [Related]
18. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201.
Maublant JC; Zhang Z; Rapp M; Ollier M; Michelot J; Veyre A
J Nucl Med; 1993 Nov; 34(11):1949-52. PubMed ID: 8229240
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
20. False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastoma.
Ozcan Z; Erenel G; Aksoylar S; Kansoy S; Burak Z; Ozkiliç H
Clin Nucl Med; 1999 Apr; 24(4):267-70. PubMed ID: 10466525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
